Muthiah Vaduganathan, MD, MPH

Guidelines across cardiology, nephrology, and endocrinology now converge on SGLT2 inhibitors as foundational CKM therapy, yet education gaps, access barriers, and clinical inertia continue to slow how quickly that consensus reaches everyday practice.

SGLT2 inhibitors have moved from a diabetes-specific therapy to a guideline-endorsed foundation of cardio-kidney-metabolic care, with generic availability now accelerating access among clinicians and patients who previously faced real barriers to these therapies.